A brief history of insulin resistance: From the first insulin radioimmunoassay to selectively targeting protein kinase C pathways

Metabolism: Clinical and Experimental

Volumn 61, Issue 4, 2012, Pages 445-449

  Aronis, Konstantinos N ^a   Mantzoros, Christos S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H IMIDAZOLE 4 CARBOXAMIDE 5 AMINO 1 [2,3 DIHYDROXY 4 61 [(PHOSPHONOOXY)METHYL]CYCLOPENTYL] [1 (1A,2B,3B,4A)]; AUROTHIOMALATE; PROTEIN KINASE C IOTA; PROTEIN KINASE C LAMBDA; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

FATTY LIVER; GLUCOSE METABOLISM; HETEROZYGOTE; HOMOZYGOTE; HYPERLIPIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RADIOIMMUNOASSAY; REVIEW;

EID: 84858447990     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.01.001     Document Type: Editorial

References (74)

1. R.S. Yalow, and S.A. Berson Immunoassay of endogenous plasma insulin in man J Clin Invest 39 1960 1157 1175
2. R.S. Yalow, and S.A. Berson Plasma insulin concentrations in nondiabetic and early diabetic subjects. Determinations by a new sensitive immuno-assay technic Diabetes 9 1960 254 260
3. C.R. Kahn, D.M. Neville Jr., and J. Roth Insulin-receptor interaction in the obese-hyperglycemic mouse. A model of insulin resistance J Biol Chem 248 1973 244 250
4. I.D. Goldfine, C.R. Kahn, D.M. Neville Jr., J. Roth, M.M. Garrison, and R.W. Bates Decreased binding of insulin to its receptors in rats with hormone induced insulin resistance Biochem Biophys Res Commun 53 1973 852 857
5. C.R. Kahn, J.S. Flier, R.S. Bar, J.A. Archer, P. Gorden, and M.M. Martin The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man N Engl J Med 294 1976 739 745
6. C.S. Mantzoros, and J.S. Flier Insulin resistance: the clinical spectrum Adv Endocrinol Metab 6 1995 193 232
7. N.A. Tritos, and C.S. Mantzoros Clinical review 97: syndromes of severe insulin resistance J Clin Endocrinol Metab 83 1998 3025 3030 (Pubitemid 28500929)
8. C.G. Fiorenza, S.H. Chou, and C.S. Mantzoros Lipodystrophy: pathophysiology and advances in treatment Nat Rev Endocrinol 7 2011 137 150
9. D.E. Moller, and J.S. Flier Insulin resistance-mechanisms, syndromes, and implications N Engl J Med 325 1991 938 948
10. A. Dunaif, J. Xia, C.B. Book, E. Schenker, and Z. Tang Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome J Clin Invest 96 1995 801 810
11. M. Christos Mantzoros Insulin resistance: definition and clinical spectrum D.S. Basow, UpToDate 19.3 ed. 2011 UpToDate Waltham, MA
12. S.J. Moschos, and C.S. Mantzoros The role of the IGF system in cancer: from basic to clinical studies and clinical applications Oncology 63 2002 317 332 (Pubitemid 36151524)
13. D. Barb, C.J. Williams, A.K. Neuwirth, and C.S. Mantzoros Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence Am J Clin Nutr 86 2007 s858 s866
14. C. Duggan, M.L. Irwin, L. Xiao, K.D. Henderson, A.W. Smith, and R.N. Baumgartner Associations of insulin resistance and adiponectin with mortality in women with breast cancer J Clin Oncol 29 2011 32 39
15. L.A. Healy, A.M. Ryan, P. Carroll, D. Ennis, V. Crowley, and T. Boyle Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer Clin Oncol (R Coll Radiol) 22 2010 281 288
16. S.C. Larsson, C.S. Mantzoros, and A. Wolk Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 121 2007 856 862 (Pubitemid 47106217)
17. J.K. Burzawa, K.M. Schmeler, P.T. Soliman, L.A. Meyer, M.W. Bevers, and T.L. Pustilnik Prospective evaluation of insulin resistance among endometrial cancer patients Am J Obstet Gynecol 204 2011 355.e351 355.e357
18. E. Friberg, N. Orsini, C.S. Mantzoros, and A. Wolk Diabetes mellitus and risk of endometrial cancer: a meta-analysis Diabetologia 50 2007 1365 1374 (Pubitemid 46879010)
19. E. Friberg, C.S. Mantzoros, and A. Wolk Diabetes and risk of endometrial cancer: a population-based prospective cohort study Cancer Epidemiol Biomarkers Prev 16 2007 276 280 (Pubitemid 46383346)
20. A.G. Antoniadis, E.T. Petridou, C.N. Antonopoulos, N. Dessypris, P. Panagopoulou, and J.P. Chamberland Insulin resistance in relation to melanoma risk Melanoma Res 21 2011 541 546
21. E.T. Petridou, T.N. Sergentanis, C.N. Antonopoulos, N. Dessypris, I.L. Matsoukis, and K. Aronis Insulin resistance: an independent risk factor for lung cancer? Metabolism 60 2011 1100 1106
22. I.F. Godsland, K. Lecamwasam, and D.G. Johnston A systematic evaluation of the insulin resistance syndrome as an independent risk factor for cardiovascular disease mortality and derivation of a clinical index Metabolism 60 2011 1442 1448
23. G.M. Reaven Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences J Clin Hypertens (Greenwich) 13 2011 238 243
24. P. Paramsothy, R. Knopp, A.G. Bertoni, M.Y. Tsai, T. Rue, and S.R. Heckbert Combined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the Multi-Ethnic Study of Atherosclerosis Metabolism 58 2009 212 219
25. G. Reyes-Soffer, S. Holleran, M.R. Di Tullio, S. Homma, B. Boden-Albala, and R. Ramakrishnan Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus Metabolism 59 2010 1365 1371
26. H.N. Ginsberg Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis Diabetes Care 14 1991 839 855
27. M.R. Taskinen Diabetic dyslipidaemia: from basic research to clinical practice Diabetologia 46 2003 733 749
28. H.N. Ginsberg Insulin resistance and cardiovascular disease J Clin Invest 106 2000 453 458 (Pubitemid 30666377)
29. H.N. Ginsberg, Y.L. Zhang, and A. Hernandez-Ono Regulation of plasma triglycerides in insulin resistance and diabetes Arch Med Res 36 2005 232 240 (Pubitemid 40755136)
30. M. Merkel, R.H. Eckel, and I.J. Goldberg Lipoprotein lipase: genetics, lipid uptake, and regulation J Lipid Res 43 2002 1997 2006 (Pubitemid 35471065)
31. R. Streicher, J. Kotzka, D. Muller-Wieland, G. Siemeister, M. Munck, and H. Avci SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I J Biol Chem 271 1996 7128 7133 (Pubitemid 26104151)
32. D.C. Chan, and G.F. Watts Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box Metabolism 61 2012 3 11
33. T. Pollare, H. Lithell, and C. Berne Insulin resistance is a characteristic feature of primary hypertension independent of obesity Metabolism 39 1990 167 174 (Pubitemid 20053276)
34. O.T. Raitakari, K.V. Porkka, T. Ronnemaa, M. Knip, M. Uhari, and H.K. Akerblom The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. The Cardiovascular Risk in Young Finns Study Diabetologia 38 1995 1042 1050
35. N.K. Lima, F. Abbasi, C. Lamendola, and G.M. Reaven Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension Am J Hypertens 22 2009 106 111
36. F.S. Facchini, C. DoNascimento, G.M. Reaven, J.W. Yip, X.P. Ni, and M.H. Humphreys Blood pressure, sodium intake, insulin resistance, and urinary nitrate excretion Hypertension 33 1999 1008 1012 (Pubitemid 29186400)
37. M.C. Stuhlinger, F. Abbasi, J.W. Chu, C. Lamendola, T.L. McLaughlin, and J.P. Cooke Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor JAMA 287 2002 1420 1426 (Pubitemid 34250505)
38. P. De Meyts, and J. Whittaker Structural biology of insulin and IGF1 receptors: implications for drug design Nat Rev Drug Discov 1 2002 769 783 (Pubitemid 37361561)
39. M.F. White The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action Recent Prog Horm Res 53 1998 119 138 (Pubitemid 128472739)
40. C.M. Taniguchi, B. Emanuelli, and C.R. Kahn Critical nodes in signalling pathways: insights into insulin action Nat Rev Mol Cell Biol 7 2006 85 96 (Pubitemid 43278292)
41. A.M. Valverde, D.J. Burks, I. Fabregat, T.L. Fisher, J. Carretero, and M.F. White Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes Diabetes 52 2003 2239 2248 (Pubitemid 37059493)
42. K. Ueki, T. Yamauchi, H. Tamemoto, K. Tobe, R. Yamamoto-Honda, and Y. Kaburagi Restored insulin-sensitivity in IRS-1-deficient mice treated by adenovirus-mediated gene therapy J Clin Invest 105 2000 1437 1445 (Pubitemid 30322409)
43. M.P. Sajan, M.L. Standaert, A. Miura, C.R. Kahn, and R.V. Farese Tissue-specific differences in activation of atypical protein kinase C and protein kinase B in muscle, liver, and adipocytes of insulin receptor substrate-1 knockout mice Mol Endocrinol 18 2004 2513 2521 (Pubitemid 39335985)
44. R.V. Farese, M.P. Sajan, H. Yang, P. Li, S. Mastorides, and W.R. Gower Jr. Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes J Clin Invest 117 2007 2289 2301 (Pubitemid 47219574)
45. M. Matsumoto, W. Ogawa, K. Akimoto, H. Inoue, K. Miyake, and K. Furukawa PKClambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity J Clin Invest 112 2003 935 944 (Pubitemid 38063751)
46. S. Frojdo, H. Vidal, and L. Pirola Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans Biochim Biophys Acta 1792 2009 83 92
47. X.J. Liu, A.B. He, Y.S. Chang, and F.D. Fang Atypical protein kinase C in glucose metabolism Cell Signal 18 2006 2071 2076
48. P. Geraldes, and G.L. King Activation of protein kinase C isoforms and its impact on diabetic complications Circ Res 106 2010 1319 1331
49. U. Kikkawa, A. Kishimoto, and Y. Nishizuka The protein kinase C family: heterogeneity and its implications Annu Rev Biochem 58 1989 31 44 (Pubitemid 19172963)
50. P. Xia, T. Inoguchi, T.S. Kern, R.L. Engerman, P.J. Oates, and G.L. King Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia Diabetes 43 1994 1122 1129 (Pubitemid 24265474)
51. R.T. Watson, M. Kanzaki, and J.E. Pessin Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes Endocr Rev 25 2004 177 204 (Pubitemid 38501393)
52. L.V. Ravichandran, D.L. Esposito, J. Chen, and M.J. Quon Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin J Biol Chem 276 2001 3543 3549
53. M.R. Sommerfeld, S. Metzger, M. Stosik, N. Tennagels, and J. Eckel In vitro phosphorylation of insulin receptor substrate 1 by protein kinase C-zeta: functional analysis and identification of novel phosphorylation sites Biochemistry 43 2004 5888 5901 (Pubitemid 38623622)
54. K. Moeschel, A. Beck, C. Weigert, R. Lammers, H. Kalbacher, and W. Voelter Protein kinase C-zeta-induced phosphorylation of Ser318 in insulin receptor substrate-1 (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1 J Biol Chem 279 2004 25157 25163 (Pubitemid 38756765)
55. M. Beeson, M.P. Sajan, M. Dizon, D. Grebenev, J. Gomez-Daspet, and A. Miura Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3, 4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise Diabetes 52 2003 1926 1934 (Pubitemid 36919783)
56. S. Perrini, J. Henriksson, J.R. Zierath, and U. Widegren Exercise-induced protein kinase C isoform-specific activation in human skeletal muscle Diabetes 53 2004 21 24 (Pubitemid 38044693)
57. N. Hashimoto, Y. Kido, T. Uchida, T. Matsuda, K. Suzuki, and H. Inoue PKClambda regulates glucose-induced insulin secretion through modulation of gene expression in pancreatic beta cells J Clin Invest 115 2005 138 145 (Pubitemid 40385514)
58. PKC-DRS Study Group The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial Diabetes 54 2005 2188 2197
59. PKC-DRS Study Group Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial Arch Ophthalmol 125 2007 318 324
60. R.G. Langham, D.J. Kelly, R.M. Gow, Y. Zhang, A.J. Cox, and W. Qi Increased renal gene transcription of protein kinase C-beta in human diabetic nephropathy: relationship to long-term glycaemic control Diabetologia 51 2008 668 674
61. K.R. Tuttle, G.L. Bakris, R.D. Toto, J.B. McGill, K. Hu, and P.W. Anderson The effect of ruboxistaurin on nephropathy in type 2 diabetes Diabetes Care 28 2005 2686 2690 (Pubitemid 43951160)
62. A.I. Vinik, V. Bril, P. Kempler, W.J. Litchy, S. Tesfaye, and K.L. Price Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial Clin Ther 27 2005 1164 1180 (Pubitemid 41393912)
63. J.B. McGill, G.L. King, P.H. Berg, K.L. Price, K.A. Kles, and E.J. Bastyr Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin Expert Opin Drug Saf 5 2006 835 845 (Pubitemid 44669498)
64. J.A. Beckman, A.B. Goldfine, M.B. Gordon, L.A. Garrett, and M.A. Creager Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans Circ Res 90 2002 107 111 (Pubitemid 34074616)
65. N.N. Mehta, M. Sheetz, K. Price, L. Comiskey, S. Amrutia, and N. Iqbal Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus Cardiovasc Drugs Ther 23 2009 17 24
66. S.P. Soltoff Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta Trends Pharmacol Sci 28 2007 453 458 (Pubitemid 47371266)
67. T. Yonezawa, R. Kurata, M. Kimura, and H. Inoko PKC delta and epsilon in drug targeting and therapeutics Recent Pat DNA Gene Seq 3 2009 96 101
68. H.J. Mackay, and C.J. Twelves Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 7 2007 554 562 (Pubitemid 46985395)
69. M.P. Sajan, S. Mastorides, M. Acevedo-Duncan, C.R. Kahn, U. Braun, and M. Leitges Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome and type 2 diabetes by inhibitors of hepatic protein kinase C-iota Metabolism 2012 Jan 5. [Epub ahead of print].
70. P. Pillai, S. Desai, R. Patel, M. Sajan, R. Farese, and D. Ostrov A novel PKC-iota inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma Int J Biochem Cell Biol 43 2011 784 794
71. E. Erdogan, T. Lamark, M. Stallings-Mann, J. Lee, M. Pellecchia, and E.A. Thompson Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota J Biol Chem 281 2006 28450 28459 (Pubitemid 44414558)
72. S. Bluher, M. Ziotopoulou, J.W. Bullen Jr., S.J. Moschos, L. Ungsunan, and E. Kokkotou Responsiveness to peripherally administered melanocortins in lean and obese mice Diabetes 53 2004 82 90 (Pubitemid 38044701)
73. S. Bluher, S. Moschos, J. Bullen Jr., E. Kokkotou, E. Maratos-Flier, and S.J. Wiegand Ciliary neurotrophic factorAx15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice Diabetes 53 2004 2787 2796 (Pubitemid 39425903)
74. C.S. Mantzoros, R.C. Frederich, D. Qu, B.B. Lowell, E. Maratos-Flier, and J.S. Flier Severe leptin resistance in brown fat-deficient uncoupling protein promoter-driven diphtheria toxin A mice despite suppression of hypothalamic neuropeptide Y and circulating corticosterone concentrations Diabetes 47 1998 230 238 (Pubitemid 28079979)